Pasar al contenido principal

CONEXIONES MOLECULARES ENTRE DIABETES Y CANCER Y POTENCIAL TERAPEUTICO DE LA VITAMINA D

PID2023-151128OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD REY JUAN CARLOS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeted radioiodine therapy of ovarian cancer via the sodium/iodide symporter (NIS)

  • Mirela Mielu, Lidia
  • Rodal-Bravo, Lucía
  • Diego-Hernández, Cristina
  • Varona, Sarai
  • Fajardo-Delgado, Dánae
  • Hortiguela, Rafael
  • Torres-Ruiz, Mónica
  • Cuesta, Isabel
  • Pallares, Pilar
  • Santisteban, Pilar
  • García-Jiménez, Custodia
  • Martín-Duque, Pilar
  • Vieja, Antonio de la
[Objective] Ovarian cancer is the most lethal gynecological malignancy, but current treatments have not improved overall survival and recurrence rates. New therapies are needed and, in this context, we propose the use of the sodium/iodide symporter (NIS) that enables effective targeted Radioiodide therapy (RAI), as NIS is overexpressed in ovarian cancer., [Methods] Using datasets and patient samples of human ovarian tumors, we determine the expression of NIS and canonical epithelial markers. We characterized NIS expression and function in human derived cell lines and tested the in vivo functional expression of NIS using Single Photon Emission Computed Tomography (SPECT). We also compared the efficacy of RAI versus chemotherapeutic treatments (cisplatin and paclitaxel) in mouse models., [Results] Human ovarian tumors expressed NIS, predominantly in a non-glycosylated form, with plasma membrane localization. Datasets and RNAseq confirmed NIS expression in ovarian epithelial tumors. Functional NIS expression was observed both in vitro and in vivo. In preclinical ovarian cancer mouse models, RAI therapy with 131I greatly reduced or eliminated tumors, was more effective, and had fewer secondary effects than classical treatments (cisplatin and paclitaxel), although both could be combined., [Conclusions] Our findings highlight that RAI through NIS could serve as a therapeutic agent in ovarian cancer. Additionally, it may enable non-invasive imaging and monitoring of disease progression., This work was supported by grants from the Spanish Ministerio de Ciencia e Innovacion (MICIN) and Fondo Europeo de Desarrollo Regional (FEDER) RTI2018–099343-B-100 and PID2023-151128OB-I00/AEI/10.13039/501100011033 to ADlV., PID2019–105303RBI00/AEI/10.13039/501100011033 to P.S., and PID2019–104867RB-I00/AEI/10.13039/501100011033 and PRECICOLON-CM P2022/BMD7212 to C.G-J., as well as CIBERONC CB16/12/00326 from Instituto de Salud Carlos III (ISCIII) to ADlV and P.S. Predoctoral fellowship from CIBERONC to L.M.M. Instituto de Salud Carlos III (ISCIII) (AESI 2024 PI24CIII/00046) and AECC grants Aragon/FEDER 2014–2020 “Building Europe from Aragon”, Spain to PM-D. This work was performed as partial fulfillment of the doctoral thesis of LMM at the Universidad Autonoma de Madrid (UAM) in Spain., Peer reviewed